Table 7.2Dopamine agonist (DA) compared with levodopa (LD) treatment (1+)

OutcomeDA versus LD
Quality of Life (PDQUALIF and EuroQol scores)NS158
UPDRS totalNS150
PPX158
UPDRS motor (III)NS151
PPX158, RP152
UPDRS ADL (II)NS152,118
PPX158
Hoehn and YahrNS153,154
Columbia ScoreNS151,155
NUDSNS155
BR153
Webster scaleNS154
BR42
Risk of developing motor complicationsCB118, BR156, PPX158
Risk of dyskinesiasNS118,151,155, BR42,152,153,156, PPX158, RP152, BR153, BR42
Risk of wearing-offNS151,155
PPX158
Risk of dystoniaNS151,158
BR153
Need for supplemental levodopaPPX158
Adverse events (all)NS118,150–152,154–156
Somnolence, oedema, hallucinationsPPX158
MortalityNS156
BR42
WithdrawalsNS 118,150–152,154,157

PPX = pramipexole; RP = ropinirole; BR = bromocriptine; CB = cabergoline; PPX/RP/BR/CB = in favour (p<0.05) of dopamine agonist treatment; LD = in favour (p<0.05) of levodopa treatment; NS = non-significant difference between treatment groups.

From: 7, Symptomatic pharmacological therapy in Parkinson’s disease

Cover of Parkinson's Disease
Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care.
NICE Clinical Guidelines, No. 35.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2006, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.